Ellingford Jamie M, Barton Stephanie, Bhaskar Sanjeev, O'Sullivan James, Williams Simon G, Lamb Janine A, Panda Binay, Sergouniotis Panagiotis I, Gillespie Rachel L, Daiger Stephen P, Hall Georgina, Gale Theodora, Lloyd I Christopher, Bishop Paul N, Ramsden Simon C, Black Graeme C M
Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, St Mary's Hospital, Manchester, UK.
Institute of Human Development, University of Manchester, Manchester, UK.
J Med Genet. 2016 Nov;53(11):761-767. doi: 10.1136/jmedgenet-2016-103837. Epub 2016 May 11.
Inherited retinal diseases (IRDs) are a clinically and genetically heterogeneous set of disorders, for which diagnostic second-generation sequencing (next-generation sequencing, NGS) services have been developed worldwide.
We present the molecular findings of 537 individuals referred to a 105-gene diagnostic NGS test for IRDs. We assess the diagnostic yield, the spectrum of clinical referrals, the variant analysis burden and the genetic heterogeneity of IRD. We retrospectively analyse disease-causing variants, including an assessment of variant frequency in Exome Aggregation Consortium (ExAC).
Individuals were referred from 10 clinically distinct classifications of IRD. Of the 4542 variants clinically analysed, we have reported 402 mutations as a cause or a potential cause of disease in 62 of the 105 genes surveyed. These variants account or likely account for the clinical diagnosis of IRD in 51% of the 537 referred individuals. 144 potentially disease-causing mutations were identified as novel at the time of clinical analysis, and we further demonstrate the segregation of known disease-causing variants among individuals with IRD. We show that clinically analysed variants indicated as rare in dbSNP and the Exome Variant Server remain rare in ExAC, and that genes discovered as a cause of IRD in the post-NGS era are rare causes of IRD in a population of clinically surveyed individuals.
Our findings illustrate the continued powerful utility of custom-gene panel diagnostic NGS tests for IRD in the clinic, but suggest clear future avenues for increasing diagnostic yields.
遗传性视网膜疾病(IRDs)是一组临床和遗传异质性疾病,全球已开发出针对此类疾病的诊断性二代测序(下一代测序,NGS)服务。
我们展示了537名接受105基因诊断性NGS检测以诊断IRDs的个体的分子检测结果。我们评估了诊断率、临床转诊的范围、变异分析负担以及IRD的遗传异质性。我们回顾性分析致病变异,包括评估外显子聚合联盟(ExAC)中的变异频率。
个体来自10种临床不同分类的IRD。在临床分析的4542个变异中,我们报告了402个突变是所检测的105个基因中62个基因的疾病病因或潜在病因。这些变异在537名转诊个体中的51%中导致或可能导致了IRD的临床诊断。144个潜在致病突变在临床分析时被鉴定为新发现的,并且我们进一步证明了已知致病变异在IRD个体中的分离。我们表明,在dbSNP和外显子变异服务器中显示为罕见的临床分析变异在ExAC中仍然罕见,并且在NGS时代后发现为IRD病因的基因在临床调查个体群体中是IRD的罕见病因。
我们的研究结果说明了定制基因panel诊断性NGS检测在临床中对IRD的持续强大效用,但也为提高诊断率指明了明确的未来方向。